A Phase 1, Open-label, Single-center, 2-part Crossover Study to Evaluate the Relative Bioavailability of Fedratinib When Administered as Contents of Capsules Dispersed in a Nutritional Supplement Orally or Via Nasogastric Tube, or Administered Orally as Divided Doses of Intact Capsules With a Nutritional Supplement in Healthy Adult Subjects
Latest Information Update: 07 Nov 2022
At a glance
- Drugs Fedratinib (Primary) ; Fedratinib (Primary)
- Indications Myelofibrosis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 27 Sep 2022 Results assessing relative bioavailability of fedratinib, presented at the 2022 American College of Clinical Pharmacology Annual Meeting.
- 22 Jun 2022 Status changed from not yet recruiting to completed.
- 22 Sep 2021 New trial record